Hepatobiliary disorder

This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The…

This phase 2 trial tests a CMV vaccine (CMV-MVA Triplex) given before a liver transplant to see if it reduces the need for antiviral drugs after surgery. The study enrolls 416 CMV-negative adults awaiting a liver transplant from a CMV-positive donor. Participants receive two vacc…

This early-stage trial tests a new vaccine called WGc0201 in 9 adults with chronic hepatitis B who are already on standard antiviral therapy. The vaccine is designed to boost the immune system to clear the virus, potentially leading to a functional cure. The main goal is to check…

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This Phase 3 trial tests elafibranor, a daily pill, against a placebo in 276 adults with primary biliary cholangitis (PBC) and cirrhosis. The goal is to see if elafibranor can prevent disease worsening, such as liver failure or death, over up to 3.5 years. Researchers will also m…

This early-stage study tests a new drug called IB-001 for chronic hepatitis B. It will first check safety in up to 60 healthy volunteers, then test multiple doses in about 30 people with chronic hepatitis B. The main goal is to see if the drug is safe and how the body handles it.

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This trial investigates whether adding a Braun anastomosis—a connection between two loops of the small intestine—during pancreatic cancer surgery can lower the risk of delayed gastric emptying, a frequent complication where the stomach takes too long to empty. About 264 adults sc…

This study compares two treatments for acute cholecystitis (inflamed gallbladder) in patients aged 75 and older. One is the standard laparoscopic surgery to remove the gallbladder. The other is a newer, less invasive procedure called EUS-guided gallbladder drainage, where a small…

This study tests whether taking a low dose of niacin (vitamin B3) after meals can help reduce fat stored in the liver for people with metabolic fatty liver disease (MASLD). Researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The goal is to see if niacin can r…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This study tests a new way to treat advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with a blood vessel blocker (bevacizumab) and standard chemotherapy, all given directly into the liver's main artery or through a vein. The goal is to see if…

This study follows 30 people with Alagille syndrome who are taking odevixibat (Bylvay) in their daily lives. The goal is to see if the drug helps them avoid serious surgeries like liver transplant or bile duct repair over the long term. Researchers will also track weight, height,…

This registry will follow 20 people in China with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their normal care. The goal is to see how safe the drug is over the long term and how well it controls symptoms like severe itching…

This trial tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery can shrink high-risk liver cancer (cholangiocarcinoma) and reduce the amount of tissue that needs to be removed. About 27 patients with resectable tumors will receive…

This study follows about 424 people with primary biliary cholangitis (PBC) who are taking elafibranor as part of their normal care. Researchers will track how well the drug controls liver damage and symptoms like itching over 5 years. The goal is to see if elafibranor works safel…

This registry will follow 10 people with progressive familial intrahepatic cholestasis (PFIC) in South Korea who are taking odevixibat (Bylvay). The goal is to see how safe and effective the drug is over the long term in real-world use. Researchers will track side effects and how…

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This Phase 3 study tests whether the drug elafibranor can slow liver damage in adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts. About 350 participants will receive either elafibranor or a placebo daily for several years. The main goal is…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This phase II trial tests whether a combination of durvalumab (an immunotherapy), chemotherapy (GEMOX or GC), followed by lenvatinib (a targeted therapy) can prevent biliary tract cancer from coming back after surgery. About 222 adults with bile duct or gallbladder cancer will be…

This study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 …

This study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after…

This study tests whether dihydroartemisinin, a drug used for malaria, can safely reduce liver fat in adults with Metabolic Associated Fatty Liver Disease (MAFLD). About 30 participants aged 18 to 45 will take the drug three times daily for 12 weeks. The main goal is to measure ch…

This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for…

This phase 3 trial tests a new drug called nanvuranlat in 480 adults with advanced biliary tract cancer that has worsened after prior treatment. Participants receive either nanvuranlat or one of several standard treatments. The main goal is to see if nanvuranlat helps people live…

This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its s…

This study tests whether placing a small tube (stent) in the pancreas during Whipple surgery can prevent a common complication called pancreatic fistula, where digestive fluid leaks out. The trial will compare 100 patients with a soft pancreas who either get the stent or not. The…

This expanded access program provides bitopertin (DISC-1459) to patients aged 12 and older with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) who have no satisfactory treatment options in the US. The goal is to offer access and gather safety information. Pa…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This study tests whether giving a higher dose of albumin (a protein) to people with advanced liver cirrhosis and fluid buildup (ascites) can reduce the need for fluid drainage procedures and prevent complications. About 100 adults with hard-to-treat ascites will receive either hi…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…

This study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…

This study follows about 200 people who receive a special stent that naturally dissolves over time to open blocked bile or pancreatic ducts. The stent is designed to avoid the need for a second procedure to remove it. Researchers track safety and how well the stent keeps the duct…

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all ne…

This study tests an injectable form of choline, a nutrient often missing in people with intestinal failure who rely on IV nutrition. The goal is to see if it can safely raise choline levels and reduce liver injury. About 129 adolescents and adults will receive either a low or hig…

This study tests whether adding alcohol use disorder treatments (acamprosate and counseling) to standard liver therapy improves outcomes for people with severe alcohol-associated hepatitis. It also compares a new drug, F-652, against prednisone for liver treatment. About 216 adul…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests whether limiting food intake to an 8-hour window each day (without counting calories) can reduce liver fat in people with obesity and a type of fatty liver disease called MASLD. Seventy-two participants will either follow this eating pattern plus standard advice,…

This study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This phase II trial is testing a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—as a first treatment for people with advanced or metastatic biliary tract cancer that has HER2 markers. The study aims to see how well the drugs shrink tumors and contro…

This Phase 2a trial is testing a new drug called ALN-PNP, alone or with a weight-loss drug (tirzepatide), in 204 adults with a specific genetic form of fatty liver disease (MASLD). The goal is to see if lowering a certain liver protein can reduce liver fat. Participants must have…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This Phase 2 trial is testing two doses (20 mg and 16 mg) of the oral drug futibatinib in 120 people with advanced bile duct cancer that has specific FGFR2 gene changes. Participants must have already tried standard chemotherapy. The study aims to see which dose works better at s…

This study tests whether adding calcitriol to vitamin D2 helps children with cholestatic liver disease correct their vitamin D deficiency faster than vitamin D2 alone. Cholestasis makes it hard for the body to absorb vitamin D. The trial will enroll 54 children and track vitamin …

This study tests an experimental drug called AZD2389 in about 104 adults with fatty liver disease and advanced liver scarring (fibrosis). The drug is a pill that blocks a protein linked to scarring. Researchers will check if it safely lowers markers of liver damage over 24 weeks …

This phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This large phase 3 study is testing whether two drugs, tirzepatide and retatrutide, can prevent major liver complications in 4,500 adults with high-risk metabolic fatty liver disease (MASLD). Participants are randomly assigned to receive one of the drugs or a placebo for about 4 …

This study tests a drug called zanzalintinib in people with advanced liver cancer that has spread or cannot be cured. The trial has two parts: first, finding the safest dose, then checking if it helps control the cancer. About 59 participants will take the drug by mouth, and rese…

This study is testing a telemedicine program called Vet-CALD for Veterans with advanced liver disease. The program pairs patients with a nurse care counselor who helps them understand their illness, set personal health goals, and coordinate care between their regular doctors and …

The UNMASK study is testing whether a 16-week program of Mediterranean diet and regular exercise can reduce liver fat and scarring in people with metabolic fatty liver disease (MASLD). Researchers will enroll 450 adults and track changes in liver health using scans and blood test…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors a…

This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize a…

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by 70%, can help reverse fatty liver disease (MASH) in people with obesity. Researchers will compare ESG plus lifestyle changes to lifestyle changes alo…

This study follows 230 children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC) who are taking Livmarli, a drug to reduce bile buildup and itching. Researchers will monitor side effects, liver function, and long-term outcomes like need for transplan…

This study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …

This study is tracking 100 adults with a rare and aggressive bile duct cancer that has a specific IDH1 gene mutation. Participants will take the targeted drug ivosidenib, which was recently approved in Europe. Researchers will monitor how long the cancer stays under control, over…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This study is testing whether giving chemotherapy (capecitabine or S-1) together with radiation after surgery can help prevent bile duct and gallbladder cancers from coming back. It includes 92 patients whose cancers had high-risk features, like positive lymph nodes or narrow sur…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…

This study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…

This Phase 3 trial tests whether seladelpar, a daily pill, can improve outcomes for people with primary biliary cholangitis (PBC) who also have compensated cirrhosis. About 318 adults will receive either seladelpar or a placebo for up to 36 months. The study tracks serious events…

This study tests whether adding the anti-inflammatory drug celecoxib to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer without their disease getting worse. The trial focuses on patients whose tumors have high levels of a marker …

This study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…

This early-stage trial is testing an experimental drug called GIGA-2339 in 48 adults with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either GIGA-2339 or a placebo by IV infusion, and researchers will…

This Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will…

This study investigates whether reducing calories to lower fat in the liver and muscles can improve how the body responds to insulin. Researchers will measure changes in insulin sensitivity and fat levels in 250 healthy but insulin-resistant adults with a family history of type 2…

This study looks at whether adding addiction counseling and monitoring after a liver transplant for alcohol-related liver disease can lower the chance of drinking again. About 720 adults who had a liver transplant for alcohol-related disease will be followed for two years. The go…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This study tests whether combining procedures that block blood flow to liver tumors (TACE or HAIC) with targeted drugs and immunotherapy can help control advanced hepatocellular carcinoma that cannot be surgically removed. The trial enrolls adults aged 18–80 with large or vein-in…

This study tests a new way to give chemotherapy for gastrointestinal cancers like colorectal and stomach cancer. Doctors will adjust the dose of one chemo drug (5-FU) based on how well each patient tolerates it, aiming to give higher doses to those who can handle it without sever…

This study tests a new stent that slowly dissolves over time to open narrowed or blocked bile ducts. About 100 people with bile duct strictures will receive the stent during a routine procedure. Researchers will track safety, how well the stent works, and whether patients feel be…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…

This study looks at whether adding lidocaine to standard sedation during radiofrequency ablation for liver cancer can reduce inflammation and lower the chance of the cancer returning. The researchers focus on a process called NETosis, which is linked to tumor growth and spread. O…

This study tests a combination of two drugs (apatinib and adebrelimab) plus chemotherapy (GEMOX) as a first treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tum…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-stage study tests a new drug called ALN-BCAT, given alone or with the immunotherapy Keytruda, in people with advanced or metastatic liver cancer that has a specific genetic mutation (WNT pathway). The trial aims to find safe doses and see if the drugs shrink tumors. Ab…

This study tests whether giving extra albumin (a protein in the blood) after a liver transplant can prevent acute kidney injury. About 400 adult liver transplant recipients will be split into two groups: one gets albumin to keep levels above 30 g/L for five days, the other only g…

This study tests whether the drug maridebart cafraglutide can reduce liver fat and body weight in adults who are overweight or obese and have high liver fat. Participants will also follow a reduced-calorie diet and increase physical activity. The trial involves 180 adults and las…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This study tests whether a blood-filtering device called DPMAS can help people with acute-on-chronic liver failure, a life-threatening condition. The device removes toxins and inflammatory substances from the blood, which may improve immune function and survival. Forty intensive …

This large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…

This study tests whether bumetanide is better than furosemide at removing excess fluid in adults hospitalized with cirrhosis. About 500 participants will receive one of the two diuretics as part of standard care. The main goal is to see which drug leads to greater weight loss by …

This phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This study tests whether tirzepatide, a drug approved for weight management, can help people with alcohol use disorder and related liver disease drink less and improve liver health. 120 adults will receive weekly injections of tirzepatide or a placebo for 12 weeks. Researchers wi…

This study tests a new biologic drug called HH-006 in 45 adults with chronic hepatitis B. Participants receive injections for 48 weeks, and researchers track how well the drug lowers hepatitis B surface antigen (HBsAg) levels. The goal is to see if the drug can control the infect…

This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects.…

This study tests a new drug called HH-009 in people with advanced liver cancer that has worsened after other treatments. About 30 participants will receive one of two doses to see if it can slow or stop cancer growth. The goal is to find out if the drug is safe and effective.

This study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main …

This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The m…

This early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…

This early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract can…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor…

This study is checking how well a device called the Cera Vascular Plug works and if it is safe. The plug is used to block blood flow in certain blood vessels to treat conditions like aneurysms, abnormal connections between arteries and veins, and other problems. About 132 adults …

This study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capec…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study tests a program called MiWeigh that helps people with obesity and related conditions like diabetes or high blood pressure lose weight. Participants get a personalized plan from a doctor, access to a website, and weekly check-ins. The goal is to see if this approach lea…

This Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study comp…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This study tests a therapeutic vaccine called TherVacB in 81 adults with chronic hepatitis B who are already on antiviral medication. The vaccine is given as a series of shots to boost the immune system and lower hepatitis B virus levels. The main goals are to check safety and se…

This study is testing a new robotic system that uses just one small incision to perform surgeries on the liver, pancreas, stomach, and esophagus. The goal is to see if this single-port approach is safe and works well for these complex operations. The study will enroll 35 adults w…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study tests whether adding immunotherapy (adebrelimab) to different chemotherapy or targeted therapy regimens can help prevent cancer recurrence in people with intrahepatic cholangiocarcinoma who have a high risk of the cancer coming back after surgery. About 90 participants…

This study looks at whether a plant-based (vegan) diet can help children with autoimmune hepatitis achieve disease remission. Researchers will compare a vegan diet to a standard high-protein diet over 180 days in 40 newly diagnosed children. The goal is to see if diet changes can…

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…

This study tests whether eating 50 grams of peanuts daily for 12 weeks can improve liver markers and gut health in adults with metabolic fatty liver disease (MASLD). 125 participants will be randomly assigned to either eat peanuts or stick to their regular diet. Researchers will …

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the disease will receive multiple doses to see if the drug can reduce virus levels and improve liver hea…

This study tests a new drug called BL-B01D1, alone or with other cancer drugs, in 74 people with advanced liver cancer that has spread. The goal is to see if these combinations can shrink tumors and how safe they are. Participants will receive the drugs through an IV or as pills …

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This phase 2 trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) works better than STRIDE alone for people with advanced liver cancer that cannot be surgically removed. About 140 adults who have not had prior systemic therapy will be enrolle…

This early-phase trial is testing a combination of three treatments for people with advanced biliary tract cancer that cannot be surgically removed. The approach delivers chemotherapy directly to the liver, along with an immunotherapy drug and a targeted therapy pill. The study a…

This study looks at whether starting hepatitis C treatment during pregnancy is feasible and acceptable for women who have used drugs. Fifty pregnant adults with hepatitis C will take glecaprevir-pibrentasvir daily for 56 days. Researchers will track how well participants stick to…

This study compares two ways of placing a stent in the liver to prevent repeat bleeding from swollen veins in the throat or stomach in people with cirrhosis. The standard method fully expands the stent, while the new method uses a smaller balloon to keep it slightly narrower. The…

This phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This study tests whether a combined computer- and counselor-delivered alcohol treatment program can help people who receive an early liver transplant for severe alcoholic hepatitis stay alcohol-free. Researchers will compare this program to standard care in 200 participants, trac…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This phase 2 trial is testing whether an artificial intelligence system can find the best doses of three drugs (irinotecan, sonidegib, and sorafenib) for people with advanced liver cancer. The study will enroll 12 adults whose cancer has not responded to other treatments. The goa…

This study tests a culturally tailored support program for Black patients with early-stage liver cancer. The program includes education, help with social needs, and easier access to cancer specialists. Forty participants will be randomly assigned to the program or usual care and …

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study compares a precise radiation technique called SABR against standard treatments (like heat probes or chemo injections) for early-stage liver cancer. About 218 adults with a single tumor up to 8 cm will be randomly assigned to SABR or standard care. The main goal is to s…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This study tests a new drug, pegozafermin, in 1,350 adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if the drug can improve scarring or resolve liver inflammation without making the disease worse over 52 weeks. Par…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…

This study tests whether a fecal microbiota transplant (FMT) can help liver cancer patients who stopped responding to standard drugs. Fifteen adults with advanced liver cancer will receive FMT along with atezolizumab and bevacizumab to see if the combination can restore tumor con…

This study tests whether rosuvastatin, a cholesterol-lowering drug, can safely slow or stop liver scarring (cirrhosis) compared to a placebo. About 256 adults with compensated cirrhosis will take the drug or placebo for 2 years. The main goal is to measure changes in liver stiffn…

This early-stage trial is testing the drug sacituzumab govitecan in 30 people with advanced solid tumors who also have moderate liver impairment. The main goal is to find a safe starting dose by monitoring side effects and how the drug moves through the body. Participants receive…

This early-stage study tests an injection called AHB-171 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it shows any signs of controlling the virus. About 110 participants will be enrolle…

This study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a p…

This study tests two diet approaches—essential amino acids and a low-sugar diet—in teens aged 11-17 with fatty liver disease and heart risk. The goal is to reduce liver fat and improve health. Participants will be assigned to one or both diets over time to find the best treatment…

This study tests a new drug, MP0317, combined with standard chemotherapy and immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps keep the cancer from growing for at least 12 months. About 75 adult…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This phase 3 trial tests whether adding N-acetylcysteine or extending prednisolone treatment beyond the standard 30 days can improve outcomes for people with severe alcoholic hepatitis. About 477 participants will be enrolled. The goal is to see if these strategies increase the n…

This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…

This Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…

This study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …

This early-phase study tests a new cell therapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not responded to standard treatments. The therapy uses the patient's own immune T cells, enhanced with a protein called CD160 to better target …

This study tests whether a daily orange peel fermentation supplement can lower body fat in 124 overweight adults with fatty liver. Participants take one sachet per day for two months. Researchers will measure changes in body fat, cholesterol, and other health markers.

This study tests whether biodegradable stents can safely open narrowed bile ducts in 20 people with primary sclerosing cholangitis (PSC). The stents are placed during an endoscopic procedure and dissolve over time, aiming to improve symptoms like itching and fatigue and prevent t…

This study compares two approaches for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity. Half of the 48 participants will receive vertical sleeve gastrectomy surgery along with lifestyle counseling, while the other half will get lifestyle…

This early-stage study tests whether bicalutamide, a drug that blocks male hormones, can improve liver health in women aged 18-42 who have both polycystic ovary syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD). About 50 participants will receive either bicalutamide or…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track ho…

This study tests a combination of three drugs—chemotherapy infused directly into the liver, a targeted pill, and an immunotherapy—in 38 people with advanced liver cancer that has spread into the main portal vein. The goal is to shrink the tumor enough so that surgeons can remove …

This early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…

This study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). The trial will involve 144 adults with biopsy-confirmed NASH and liver scarring. Participants will …

This study tests a new approach for people with a certain type of bile duct cancer that cannot be removed by surgery. Participants first receive chemotherapy and radiation, then a liver transplant. The goal is to see if this combination helps patients live longer and stay cancer-…

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This phase 2 trial is testing whether adding a procedure called radiofrequency ablation (bRFA) to standard chemotherapy and immunotherapy is safe for people with bile duct cancer that cannot be removed by surgery. About 36 participants will be randomly assigned to receive either …

This study is for adults with advanced liver cancer (hepatocellular carcinoma) that is hard to treat. It compares two standard drug regimens — immunotherapy (atezolizumab + bevacizumab) or targeted pills (lenvatinib or cabozantinib) — given after a liver-directed radiation treatm…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This study tests whether using heat (radiofrequency ablation) to destroy cancer tissue inside the bile duct before placing a metal stent can keep the duct open longer than placing a stent alone. It involves 122 adults with inoperable bile duct cancer. The main goal is to see how …

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib helps shrink tumors or slow cancer growth in people with advanced liver cancer. About 80 adults whose cancer worsened after initial immunotherapy will be randomly assigned to receive eit…

This Phase 3 trial tests whether a chemotherapy infusion directly into the liver (HAIC) plus immunotherapy drugs works better than the standard chemo-embolization procedure (TACE) plus the same immunotherapy for people with intermediate-stage liver cancer that has spread extensiv…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tissue. …

This pilot study tests whether giving a combination of two growth factors (G-CSF and darbepoetin) in single or repeated cycles can improve immune function in people with early decompensated cirrhosis. Sixty participants will be randomly assigned to receive either the growth facto…

This phase 3 trial is testing whether giving a targeted therapy after initial standard chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. Participants must have a tumor with a specific genetic change and stable disease after…

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This early-stage trial is testing whether a transplant of healthy gut bacteria can be safely given to people with primary sclerosing cholangitis (PSC), a rare liver disease. Twenty-eight adults will first take antibiotics to clear their gut, then receive capsules containing freez…

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS…

This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …

This study tests whether a 4-week ketogenic diet before liver surgery can reduce fat in the liver and lower the need for blood transfusions. About 124 adults with fatty liver and colorectal cancer that spread to the liver will either follow the diet or get standard dietary advice…

This study tests whether adding a physical activity program to standard care can improve health in older women who have three conditions: underactive thyroid (hypothyroidism), glaucoma (high pressure in the eyes), and fatty liver. Researchers will measure changes in eye pressure,…

This study tests an investigational drug called TGM-312-SC01, given as a shot, for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. It first checks safety and drug levels in healthy adults, then in people with MASH. The trial is currently recrui…

This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the …

This Phase 2 trial tests a drug called ALN-HSD, which uses gene silencing to target liver scarring in people with MASH, a fatty liver disease that can lead to cirrhosis. The study enrolls 120 adults with genetic risk factors and moderate-to-severe liver fibrosis. Researchers will…

This early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. Abou…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study compares three approaches for people with both gallstones and bile duct stones: a gallbladder-preserving procedure using an endoscope, ERCP plus gallbladder removal surgery, or conservative management with medication or watchful waiting. Researchers will track complica…

This study tests a new drug called HU6 for people with MASH, a serious fatty liver disease. About 180 adults aged 30 and older will receive either HU6 or a placebo to see if the drug safely reduces liver fat. The trial lasts 26 weeks and focuses on safety and how well the drug wo…

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth…

This study looks at whether adding focused radiation to spots where cancer is growing can help people with advanced liver cancer whose first immunotherapy treatment has partly stopped working. About 30 adults with limited new growth will receive radiation to those spots while con…

This study tests whether placing a small plastic tube (stent) in the pancreas during a gallstone removal procedure can prevent pancreatitis, a painful inflammation. 88 adults with both gallbladder and common bile duct stones will be randomly assigned to receive either standard ca…

This study tests a mix of three chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy drug (durvalumab) in people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and how safe it …

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of iron-containing nanoparticles that travel to the tumor, then a machine creates a magnetic field to heat the particles and da…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study tests whether giving oral antibiotics after Kasai surgery can prevent cholangitis, a serious bile duct infection, in infants with biliary atresia. About 356 babies will be randomly assigned to receive either preventive antibiotics or standard care, and they will be fol…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This study tests whether adding empagliflozin (a diabetes drug) to standard carvedilol treatment can prevent liver decompensation events and death in 400 adults with cirrhosis and left ventricular diastolic dysfunction (stiff heart). Participants will receive either empagliflozin…

This study tests a combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has not responded to standard first-line therapy. The trial has two phases: first to find the safest dose, then to s…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This early-phase trial is testing whether combining a targeted radiation treatment (Y90 radioembolization) with two immunotherapy drugs (durvalumab and tremelimumab) is safe and shows promise for people with bile duct cancer that cannot be removed by surgery. The study will enrol…

This early-phase trial is testing a new treatment called Super CAR-T for people with advanced hepatocellular carcinoma, a type of liver cancer that has spread. The treatment involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, …

This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will …

This study tests whether two drugs that calm the immune system—high-dose steroids or anti-thymocyte globulin—can help children with sudden, severe liver failure survive without needing a liver transplant. About 163 children aged 1 to 17 will be randomly assigned to receive one of…

This project aims to make hepatitis C testing and treatment easier for people who visit drug treatment clinics and needle exchange programs. Researchers will work with clinics across New South Wales, Australia, to help more people start treatment. The study includes up to 6,000 a…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This clinical trial is testing a new drug called VRT106 combined with two other drugs (camrelizumab and apatinib) in people with advanced liver cancer that has not responded to prior immunotherapy. The study will enroll 66 participants and aims to see if the combination is safe a…

This study compares two antiviral drugs, tenofovir alafenamide (TAF) and entecavir, in 140 adults with chronic hepatitis B. The goal is to see which one controls the virus better and causes fewer kidney problems. Participants take one pill daily for about a year.

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After 3 months, researchers will compare how wel…

This study tests a powerful combination of treatments for people with advanced liver cancer that cannot be surgically removed. The approach uses heat-based ablation to destroy the main tumor, followed by targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a procedure…

This study tests a new combination of drugs (ivosidenib, durvalumab, and chemotherapy) as a first treatment for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. The goal is to see if the combination is safe and works better than st…

This study tests whether adding a precise, high-dose radiation treatment (SBRT) after a standard procedure (TACE) can better control liver cancer in people whose tumors cannot be surgically removed. About 30 adults with early- or intermediate-stage liver cancer will receive the c…

This trial tests whether a computer guidance software can help doctors more completely destroy liver tumors during microwave ablation. About 84 adults with liver cancer (HCC) will have the procedure with the software's assistance, and their outcomes will be compared to historical…

This study tests a combination of two drugs—tislelizumab (an immunotherapy) and huaier granule (a traditional Chinese medicine)—as a first treatment for people with advanced liver cancer that cannot be surgically removed. About 94 adults will receive this combination to see if it…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) can help people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults with inoperable or metastatic bile duct cancer …

This study compares two imaging methods—contrast-enhanced ultrasound and abbreviated MRI—to see which is better at detecting early-stage liver cancer (HCC) in people with suspicious but not yet cancerous liver nodules. Researchers will enroll 600 adults with cirrhosis and indeter…

This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve ear…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study aims to see which of two blood tests, eLIFT or FibroMeter, is better at finding advanced liver scarring (fibrosis) in people with fatty liver disease or alcohol-related liver disease. About 1,788 adults from primary care clinics will take both tests. The goal is to imp…

This study is testing whether adding a special PET scan (using F18-Piflufolastat) to standard imaging can better diagnose and stage liver cancer. Researchers will enroll 90 veterans with suspected or confirmed hepatocellular carcinoma. The goal is to see if the scan helps clarify…

LiverSeek is a study testing an automated screening program for advanced liver fibrosis in people aged 50-75 with risk factors like diabetes or obesity. When a routine blood test is done, the lab system automatically calculates a fibrosis score and, if needed, orders additional t…

This study tests whether a special type of CT scan (spectral CT) can better detect remaining liver cancer after a standard treatment called TACE. About 121 adults with liver cancer who have had TACE will get a spectral CT scan, and results will be compared to standard CT and to a…

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The…

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients a…

This study is testing a new ultrasound imaging method called Contrast Enhanced Super-Resolution (CESR) to see if it can better detect and tell apart cancerous and non-cancerous lesions in the breast, liver, and kidney. It involves 40 participants: 10 healthy volunteers to fine-tu…

This study is testing a new, non-invasive liver scan called iLivTouch to see if it can accurately detect a serious liver condition called MASH in people who have both type 2 diabetes and fatty liver disease. The scan measures liver inflammation, fat, and stiffness without any nee…

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study tests a dye called CYTALUX (pafolacianine) that attaches to cancer cells and glows under a special camera during surgery. About 50 adults with certain cancers (like esophageal, pancreatic, or gynecologic) will get the dye before surgery. The goal is to see if the glowi…

This study compares standard ultrasound (done on the outside of the belly) with laparoscopic ultrasound (done inside the abdomen during weight-loss surgery) to see which finds more gallstones and other gallbladder issues. The goal is to better identify patients who could benefit …

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study is collecting blood samples from 575 adults with fatty liver disease to find new, noninvasive tests that can detect liver scarring (fibrosis). Currently, doctors rely on a painful liver biopsy to check for scarring, but this research aims to replace that with a simple …

This study is testing whether proteins in the blood can help detect liver cancer at an early stage. Researchers will compare blood samples from 600 people—some with liver cancer and some healthy—to find protein patterns that signal the disease. The goal is to create a simple, non…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is testing a new, non-invasive MRI scan (called cT1) to see if it can accurately diagnose NASH, a serious liver disease. Currently, doctors need to take a small sample of liver tissue with a needle (biopsy) to confirm the diagnosis. The study will compare the MRI resul…

This study tests a new endoscopic ultrasound method (EUS-SWQ) to measure liver stiffness and diagnose liver fibrosis (scarring) in people with chronic liver disease. Researchers will compare EUS-SWQ results with standard liver biopsy and FibroScan in 65 adults. The goal is to see…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study is looking at whether a blood test called the Enhanced Liver Fibrosis (ELF) test can find early signs of fatty liver disease in people who are at high risk, such as those with diabetes, high blood pressure, or heart disease. Researchers will review medical records of 3…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study tests if a faster MRI scan, combined with a blood test, can find liver cancer earlier than the standard ultrasound in people with cirrhosis. The goal is to catch cancer at an early, more treatable stage and reduce deaths from liver cancer. About 4,700 veterans with cir…

This study tests whether semaglutide (a drug used for diabetes and weight loss) can prevent weight gain and fatty liver disease in people who have recently had a liver transplant. About 50 adults who had a transplant 2 to 6 months ago will receive either semaglutide or a placebo.…

This study combines peer navigation (trained community members) with mobile health tools to help gay, bisexual, and transgender people in rural Appalachia access HIV, STI, and hepatitis C testing and prevention services. About 141 participants will be split into two groups: one g…

This trial tests whether a different way of closing the abdominal wall during liver tumor surgery can lower the chance of developing an incisional hernia. 140 patients will be randomly assigned to receive either the new 'short stitch' method or the traditional closure. Researcher…

This pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and av…

This study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests a drug called golexanolone in 84 people with primary biliary cholangitis (PBC) who suffer from significant fatigue and cognitive problems. Participants receive either the drug or a placebo for up to 28 days. The goal is to see if the drug is safe and can improve …

This study tests a new augmented reality system called LUMENA that helps doctors guide needles during MRI scans of the liver. Twenty adults having a liver biopsy or tumor ablation will try the device. The goal is to see if it is safe and works well enough to use in most procedure…

This study compares two methods of removing the gallbladder during laparoscopic (keyhole) surgery: through a port near the belly button or one below the breastbone. The goal is to see which approach causes less pain and fewer wound problems like infection. The trial will involve …

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study compares two ways to manage pain after open liver surgery: a newer erector spinae plane block (ESPB) and the standard thoracic epidural. Sixty adults having elective open liver resection will be randomly assigned to one method. The goal is to see if ESPB provides simil…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This study compares a newer, less invasive endoscopic procedure to standard surgery for treating gastric outlet obstruction, a blockage that prevents food from leaving the stomach. The trial will enroll 32 adults with advanced cancers causing this blockage. The main goal is to se…

This study compares two types of sedation used during a procedure to drain blocked bile ducts. About 98 adults will receive either propofol-remifentanil or propofol-ketamine. The goal is to see which method leads to faster recovery, better comfort, and fewer side effects, especia…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study looks at whether a needle-free device called the J-Tip can reduce pain and anxiety during a procedure that drains fluid from the belly (paracentesis) in people with liver cirrhosis. About 110 adults will be randomly assigned to receive numbing medicine either through a…

This study compares two types of nerve blocks—erector spinae plane block and modified thoracoabdominal nerve block—for pain control after laparoscopic gallbladder removal. Fifty adults aged 30-65 will receive one of the two blocks with bupivacaine. Researchers will measure how lo…

This study tests if drinking a carbohydrate beverage before liver transplant surgery helps patients recover more quickly and spend fewer days in the hospital. About 434 adults receiving a liver transplant will be randomly assigned to drink either the carbohydrate drink or a place…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study tests a new tablet called 4-MUST to see if it reduces pain and discomfort in people with chronic gallbladder inflammation and bile duct issues. About 300 adults aged 18-70 will receive either the drug or a placebo for 29 days. The main goal is to measure pain relief us…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests an experimental drug called volixibat for people with primary biliary cholangitis (PBC) who suffer from severe itching. The trial will involve 260 adults and compare volixibat against a placebo to see if it safely reduces itch severity and improves quality of lif…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests a home monitoring program called LiverWatch for people with advanced liver disease (cirrhosis). Participants get a Fitbit, personalized nutrition advice, and weekly check-ins to boost activity and manage symptoms. The goal is to see if this approach improves qual…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…

This study looks at how the liver processes fat in people with alcohol use disorder who are quitting drinking. Researchers will take two small liver samples—one early in detox and one after four weeks—to compare gene activity. The goal is to understand how the liver clears fat wh…

This study surveys physicians in China to understand how they diagnose and manage metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. It focuses on whether and how doctors assess liver fibrosis, a key indicator of disease severity. Th…

This study looks for genetic changes linked to progressive familial intrahepatic cholestasis (PFIC) in adults with unexplained bile flow problems. Researchers will collect health information and blood samples from 150 participants across Spain during a single visit. The goal is t…

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard …

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study tests a program where patients with liver cancer meet with a navigator who helps them connect to medical and community resources. The goal is to understand patient needs and improve access to care and research participation. Adults with hepatocellular carcinoma or othe…

This study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…

This study follows 1,500 pregnant women and their children for up to 18 years to understand how a mother's health, lifestyle, and environment affect her child's growth and risk for obesity, diabetes, and fatty liver. Mothers attend visits during pregnancy and after birth, while c…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is gathering health information from 2,000 adults with primary sclerosing cholangitis (PSC) to build a real-world data comparator group. The goal is to help design and run future drug trials more efficiently by providing a control group from real patient experiences. P…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resis…

This study investigates whether measuring the thickness of the carotid artery (a major artery in the neck) before surgery can help predict blood pressure swings and complications during liver transplant operations. Researchers will measure carotid artery thickness using a simple,…

This study is observing 200 adults with advanced liver cancer who are starting a new treatment with two drugs, tremelimumab and durvalumab. Researchers want to see how long it takes for liver problems to get worse, how patients feel, and how safe the treatment is in everyday medi…

This study follows 200 obese Chinese patients undergoing weight-loss surgery to understand how nonalcoholic fatty liver disease (NAFLD) progresses. Researchers will take liver biopsies during surgery and track health markers over time. The goal is to find better ways to predict a…

This study will enroll 6,000 people with bile duct widening (choledochal cyst) from 25 hospitals in China. Researchers will track patients over time to better understand the condition, including how it progresses, cancer risks, and the best timing for surgery. The goal is to crea…

This study looks at medical records of 514 adults in India with acute cholangitis (a bile duct infection and blockage) who had a drainage procedure. The goal is to create a new composite index that combines factors like death, need for organ support, ICU stay, complications, hosp…

This study gathers international experts to agree on what makes a high-quality contrast-enhanced ultrasound (CEUS) of the liver. Using a Delphi process, they will rate and refine quality indicators. The goal is to create a standardized tool for assessing image quality, improving …

This study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…

This study looks at how the drug mirdametinib is absorbed and removed from the body in people with moderate or severe liver problems compared to those with normal liver function. It involves 32 adults and is for research only, not to treat any condition. The goal is to understand…

This study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for…

This study uses a device called FibroScan to measure liver stiffness and fat content in people with liver disease. The scan is non-invasive, like an ultrasound, and takes only a few minutes. Researchers aim to build a large database of these measurements to help improve future di…

This early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detec…

This observational study aims to see if frailty—a state of increased weakness and vulnerability—differs between men and women with MASLD (fatty liver disease). Researchers will track 140 participants over time using physical tests and questionnaires. No drugs or treatments are be…

This study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …

This study looks at a heart condition called cirrhotic cardiomyopathy that can affect people with advanced liver disease (cirrhosis). Researchers want to learn how common it is, what increases the risk, and whether bile acids in the blood play a role. About 440 adults with decomp…

This study follows 70 adults with refractory ascites (fluid buildup in the belly that doesn't respond to standard treatment) caused by liver disease or cancer. Researchers will use surveys to measure quality of life and CT scans to track muscle loss (sarcopenia) over time. The go…

This study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study looks at whether new MRI techniques can spot NASH, the serious form of fatty liver disease, without needing a liver biopsy. Researchers will scan 110 adults who already need a biopsy to see if the MRI can match the biopsy results. If successful, it could lead to a safe…

This study is building a prediction model to estimate the risk of heart injury after major liver surgery. Researchers will track 1800 patients undergoing hepatobiliary surgery and analyze factors like surgical technique and routine blood tests. The goal is to create a tool that h…

This early-stage study is testing a new tablet called 4-MUST in 45 healthy volunteers. Researchers want to see if taking the drug with food changes how much gets into the blood, and how safe and tolerable it is after single and repeated doses. The results will help design future …

This study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…

This study is creating a central database and tissue bank for rare diseases affecting the kidneys and liver, such as ARPKD and Joubert syndrome. Researchers will collect medical information, genetic samples, and tissues from 200 participants to help doctors and scientists better …

This study looks at whether giving proton pump inhibitors (like omeprazole) to people with cirrhosis who have bleeding in the esophagus causes more complications in the hospital. Researchers will randomly assign 60 adults to receive either the drug or no drug after an endoscopic …

This study is testing whether a special PET scan (18F-FSPG) and a blood test for tumor DNA can help doctors better guide treatment for liver cancer. About 60 people with hepatocellular carcinoma will receive standard Y90 radioembolization therapy. The goal is to see if these test…

This study looks at 20 adults with psoriatic arthritis and fatty liver disease to see if the drug guselkumab can improve liver fat, joint swelling, and skin plaques. Participants will have two visits over 24 weeks to track changes. The goal is to understand shared disease mechani…

This study looks at whether people born with a low birth weight have a higher chance of developing non-alcoholic fatty liver disease (NAFLD) as adults. Researchers will compare 250 low-birth-weight adults with 50 normal-birth-weight adults using liver scans and other tests. The g…

This study is collecting blood, urine, and stool samples from 300 people with cirrhosis to build a biobank. Researchers will later use these samples to understand how factors like nutrition, physical activity, smoking, alcohol, and pollution influence the development of the most …

This study aims to build an AI model that uses medical images and tissue samples to predict which liver cancer patients will benefit from additional treatments after surgery. Researchers will analyze data from 11,000 patients to see if the AI's recommendations match real-world ou…

This early-stage study is testing how the drug BMS-986435 behaves in the body and whether it is safe for people with mild to moderate liver problems compared to those with healthy livers. 24 adults will receive a single dose, and researchers will measure drug levels and monitor f…

This early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver pro…

This study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…

This early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrh…

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…

This study looks at whether using lung ultrasound right after gallbladder surgery can find breathing problems like collapsed lung tissue (atelectasis) early. About 110 adults having laparoscopic gallbladder removal with low-flow anesthesia will be checked. The goal is to see if e…

This study is gathering information from 800 people with liver cancer to track their diagnosis, treatments, and long-term health. The goal is to create a detailed database that helps doctors see what works best in real-world care. Participants must be 18 or older and treated at T…

This study compares people with non-alcoholic fatty liver disease (NAFLD) to healthy controls to understand how the immune system, metabolism, and gut bacteria differ. Researchers will also track what happens to liver health in NAFLD patients who undergo weight loss surgery. The …

This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to …

This study is creating a large database of information and samples from 1,000 infants with cholestasis, a condition that causes prolonged jaundice. The goal is to better understand diseases like biliary atresia and find ways to improve care. Researchers will track how the disease…

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study follows 1,000 children with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. Researchers will collect medical data, DNA, and symptom reports over time to understand how the disease progresses and affects daily life. The goal is to ide…

This study is collecting medical information, genetic material, and body fluid samples from over 1,200 children with biliary atresia, a rare liver disease. The goal is to find genes that cause the disease and understand how it progresses in children who still have their own liver…

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study will screen 2,000 people with HIV for fatty liver disease using a painless ultrasound technique. The goal is to catch liver problems early and improve long-term care. Researchers will also track how different HIV medications affect liver health.

This study looks at liver transplant biopsy samples to better understand and predict organ rejection. Researchers will analyze gene activity in 300 biopsy samples from transplant patients to create a tool that can identify rejection types more accurately. Participants are those a…

This study looks at whether measuring a substance called FMN in the fluid used to preserve donated livers can predict how well the liver will work after transplant. Researchers will collect samples from 850 liver transplant patients at multiple hospitals. The goal is to see if FM…

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid givi…

This study tests whether a special ultrasound done through an endoscope can measure how well beta-blockers are working in people with cirrhosis and high blood pressure in the liver. Twenty-four participants will get the ultrasound before and after three months of treatment with c…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This early-stage study looks at how the liver handles two experimental drugs, AZD9550 and AZD6234, in people with moderate to severe liver problems compared to healthy volunteers. About 28 adults will receive a single injection of one drug. The goal is to see if liver impairment …

This study is observing 400 people aged 12 and older who have noncirrhotic portal hypertension (NCPH) or are at risk for it. NCPH is a liver condition that increases blood pressure in the liver's blood vessels without causing cirrhosis, and often has no early symptoms. Researcher…

This study will follow 20,000 elderly people with fatty liver disease to learn what factors affect their health. Researchers will look at lifestyle, genetics, and environment to understand how the disease progresses. The goal is to create better risk assessment tools and preventi…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study aims to see how common fatty liver disease (MASLD) is in people with underactive thyroid (hypothyroidism) who do not have diabetes. Researchers will use blood tests, ultrasound, and a special liver scan (FibroScan) to check 200 adults. The goal is to understand if thyr…

This study looks at how cutting calories affects the way the liver processes amino acids, sugars, and fats in people with type 2 diabetes. Researchers want to see if weight loss helps the liver respond better to a hormone called glucagon. About 20 adults with type 2 diabetes and …

This study is observing 1,000 people with liver cirrhosis who have bacterial infections and are being treated with β-lactam antibiotics. Researchers want to see how the body processes these drugs and whether personalized dosing could improve survival. The study is observational, …

This early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…

This early-stage study by Pfizer looks at how different levels of liver function affect the processing of a new drug called PF-07328948. About 26 adults with and without liver impairment will take a single tablet and stay at the clinic for 6 days for monitoring and blood tests. T…

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results an…

This study aims to find tiny genetic markers (microRNAs) and blood chemicals that can tell doctors early whether a liver cancer patient will fully respond to heat-based tumor destruction. Researchers will analyze blood and tumor tissue samples from 150 adults with early-stage liv…

This study is creating a large collection of blood samples and health data from 3500 people with hepatitis B, including those who have already cleared the virus. Researchers will use these samples to look for viral RNA patterns that could signal a functional cure. No new treatmen…

This study looks at how inflammation and liver repair differ in people with alcoholic hepatitis versus those with alcoholic cirrhosis or healthy livers. Researchers will collect blood, liver tissue, and fluid samples from 450 participants. The goal is to better understand what dr…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study is looking at 1,000 liver transplant recipients to see if testing their blood, urine, and tissue samples can detect early signs of chronic kidney disease, acute rejection, or hepatitis C. The goal is to find simple biomarkers that could lead to earlier treatment and fe…

This study is creating a large database of 2000 people whose cancer has spread to the liver. Researchers will collect information on patients' health, treatments, and outcomes to learn more about the disease and improve future care. No new treatments are being tested; the goal is…

This study follows 7,500 heavy drinkers over time to learn how alcoholic liver disease develops and worsens. Researchers will use non-invasive tests like ultrasound and blood markers to identify who is at risk for cirrhosis and liver cancer. The goal is to improve screening and e…

This study is testing a two-step screening method to find advanced liver fibrosis in people who don't yet have symptoms. First, a routine blood test calculates a score called FIB-4. If that score is high, patients get a more specialized non-invasive test. The goal is to see how w…

This study creates miniature, lab-grown versions of liver cancer tumors from patient biopsies. Researchers will test how well different treatments work on these models and look at how gut health and the tumor's environment affect the disease. The goal is to better understand live…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

This study is observing heavy drinkers with jaundice to learn more about alcoholic hepatitis, a serious liver condition. Researchers will track survival and liver function over 12 months, and collect genetic samples to better understand the disease. The goal is to improve diagnos…

This study will follow 10,000 people in Australia who have chronic hepatitis B to see how well they are connected to care and treatment. Researchers will collect information from clinics across the country to understand who is getting treated and what their health needs are. No n…

This study looks at genetic changes in natural killer (NK) and B cells—key immune cells—in people with chronic hepatitis B. Researchers want to understand why these cells don't work properly during long-term infection. The study will analyze blood samples from 140 adults with chr…

This study looks at how radiation treatment for esophageal cancer affects the body's ability to respond to the pneumonia vaccine. Researchers will give the vaccine to 80 patients who have low white blood cell counts after chemoradiation. They want to see if the vaccine still work…

This study looks at images from 50 liver cancer patients who received a special dye (contrast agent) during a procedure before radiation therapy. Researchers want to see if a software program (KIM) can detect that dye in the images to better track the tumor during treatment. The …

This study is a registry that will follow 500 people with primary biliary cholangitis (PBC) in Austria. Researchers will collect medical data and optional blood or liver samples to learn how the disease progresses and what complications arise. No new treatment is being tested; th…

This study aims to find early warning signs for major chronic diseases like stroke, heart disease, and cancer by following 4,500 healthy adults aged 30-80 in Lishui. Participants will receive regular check-ups and long-term monitoring. The goal is to improve prevention and care a…

This study looks at why some pregnant women develop intrahepatic cholestasis of pregnancy (ICP), a liver condition causing severe itching and higher risks for both mother and baby. Researchers will measure bile acids and check for genetic changes in 150 Indian women with and with…

This study looks at genetic and chemical markers in fat tissue from 500 people with severe obesity who are having weight-loss surgery. Researchers collect a small amount of belly fat during the operation and take blood samples afterward. The goal is to understand why some patient…

This study will check for microplastics in liver tissue from 30 people with cirrhosis who are having surgery or a liver transplant. Researchers want to see if these tiny plastic particles are linked to worse liver damage, higher blood pressure in the liver, and heart problems. Th…

This study follows 390 adults in Zambia with hepatitis B, some also with HIV, to see how their liver and immune system change over time. Participants join when diagnosed or starting standard antiviral treatment and are monitored for years. The goal is to learn more about the dise…

This study looks at people with high blood pressure in the liver that causes swollen veins in the esophagus and stomach. Researchers will compare those who get an endoscopic procedure (using a camera down the throat) with those who receive other treatments like medicine or surger…

This study is collecting information from 10,000 liver transplant patients across Europe to create a new, up-to-date reference for what good outcomes look like when using machine perfusion (a technique that keeps donated livers healthier before transplant). The goal is to help do…

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects ov…

This study follows 1,500 people with porphyria over many years to learn how the disease progresses, what symptoms appear, and how it affects pregnancy and lifespan. Researchers will collect medical records and lab results to create a clearer picture of the condition. No new treat…

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable levels in other body fluids like saliva or semen. Researchers will compare treated patients with suppressed virus to untreated patients with active…

This study looks at how common tooth staining is in children who had very high bilirubin levels (jaundice) early in life. Researchers will check 120 children with certain liver conditions to see if their teeth are discolored and whether that affects their daily life. The goal is …

This study looks at how semaglutide, a drug used for diabetes and weight loss, changes fat tissue around the kidneys, heart, and liver in people with type 2 diabetes and chronic kidney disease. Researchers will compare patients taking semaglutide to those not taking it. The goal …

This study looks at why some adults who had the Fontan procedure as children develop serious liver scarring. Researchers will use blood tests, imaging, and liver biopsies to track changes and find early markers of disease. The goal is to better understand the process and pave the…